acalabrutinib,zanubrutinib,ibrutinib
abbvie,beigene,janssen,astrazeneca
['acalabrutinib', ' ibru', 'zanubrutinib', 'lymsm', 'zanu ', 'cll']
cost-effectiveness of ibrutinib vs acala vs zanu in frontline cll. acalabrutinib actually had greatest reduction in risk of death &amp; better qalys than other two agents. however, icurs were $500k per qaly, which were lower than icers owing to better utility/qol. #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????